|Articles|November 18, 2003
FDA approves CrystaLens, first accommodating IOL
Eyeonics inc. (formerly C&C Vision) received FDA approval to marketthe CrystaLens, the first accommodating IOL that allows patients to focusautomatically and seamlessly at all distances.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
How AI is reshaping ophthalmology in 2025 and beyond
2
8 things to know about aflibercept 8 mg for retinal vascular disease
3
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
4
Reimagining dry eye care: Focus on sustained tear production
5





































